EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy

Matilde Vale iD, Jan Prochazka, Radislav Sedlacek iD

Cells · 2024

DOI: 10.3390/cells13110920 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2024. Verfasst von Matilde Vale und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i, 252 50 Vestec, Czech Republic. Hauptthemen laut MEDLINE: Anemia, Diamond-Blackfan, Genetic Therapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Academy of Sciences, Ministry of Education, Youth and Sports (MEYS), European Union's Horizon Europe under the Marie Skłodowska-Curie grant agreement "Gene Therapy of Rare Diseases (GetRadi)".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diamond–Blackfan anemia (DBA) is a rare genetic disorder affecting the bone marrow’s ability to produce red blood cells, leading to severe anemia and various physical abnormalities. Approximately 75% of DBA cases involve heterozygous mutations in ribosomal protein (RP) genes, classifying it as a ribosomopathy, with RPS19 being the most frequently mutated gene. Non-RP mutations, such as in GATA1, have also been identified. Current treatments include glucocorticosteroids, blood transfusions, and hematopoietic stem cell transplantation (HSCT), with HSCT being the only curative option, albeit with challenges like donor availability and immunological complications. Gene therapy, particularly using lentiviral vectors and CRISPR/Cas9 technology, emerges as a promising alternative. This review explores the potential of gene therapy, focusing on lentiviral vectors and CRISPR/Cas9 technology in combination with non-integrating lentiviral vectors, as a curative solution for DBA. It highlights the transformative advancements in the treatment landscape of DBA, offering hope for individuals affected by this condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Diamond-BlackfanGenetic TherapyHumansCRISPR-Cas SystemsGenetic VectorsLentivirusAnimalsRibosomal ProteinsMutationGene Editing

Stichwörter der Autor:innen

CRISPR/Cas9Diamond–Blackfan anemiagene therapyhematopoietic stem cell transplantationlentiviral vectornon-integrating lentiviral vectorrare genetic disorderribosomal protein genesribosomopathy

Substanzen

Ribosomal Proteins

Autor:innen und Institutionen

  • Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i, 252 50 Vestec, Czech Republic.
  • Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, v.v.i, 252 50 Vestec, Czech Republic.

ORCID-Profile: Matilde Vale, Radislav Sedlacek

Förderung

  • Czech Academy of Sciences
  • Ministry of Education, Youth and Sports (MEYS)
  • European Union's Horizon Europe under the Marie Skłodowska-Curie grant agreement "Gene Therapy of Rare Diseases (GetRadi)"
  • the Czech Academy of Science
  • the Ministry of Education, Youth and Sports (MEYS)
  • European Union’s Horizon Europe under the Marie Skłodowska-Curie grant agreement “Gene Therapy of Rare Diseases (GetRadi)”

Zitieren

APA

Vale, M., Prochazka, J., & Sedlacek, R. (2024). Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy. Cells. https://doi.org/10.3390/cells13110920

Vancouver

Vale M, Prochazka J, Sedlacek R. Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy. Cells. 2024. doi:10.3390/cells13110920

BibTeX
@article{Vale2024,
  author = {Vale, Matilde and Prochazka, Jan and Sedlacek, Radislav},
  title = {Towards a Cure for Diamond–Blackfan Anemia: Views on Gene Therapy},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13110920}
}
Kostenlos starten →